Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Waxman, A. Opotowsky, L. Lawler, D. Systrom (Boston, United States Of America). An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH). Eur Respir J 2013; 42: Suppl. 57, 4059

Member's Comments

No comment yet.

Related content which might interest you: Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Patient perspectives on exercise training in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Atorvastatin in Pulmonary Arterial Hypertension (APATH) study Source: Eur Respir J 2012; 40: 67-74 Year: 2012 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Baseline hemodynamic predictors of treatment response in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Pulmonary haemodynamics during exercise in patients with pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension Year: 2005 Effects of pulmonary rehabilitation (PR) in idiopathic pulmonary arterial hypertension (PAHI) Source: Annual Congress 2013 –The latest insights in pulmonary rehabilitation (part 2) Year: 2013 Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Exercise right heart catheterisation in the diagnosis of pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Safety related to maximal cardiopulmonary exercise testing in patients with pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Recovery from dynamic exercise dissociates ventilatory from pulmonary gas exchange responses in patients with chronic thromboembolic pulmonary hypertension Source: Annual Congress 2013 –Mechanisms contributing to exercise limitation in health and respiratory, cardiac and pulmonary vascular diseases Year: 2013 Riociguat improves excessive exercise ventilation in patients with inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Relationship between exercise desaturation and pulmonary haemodynamics in COPD patients Source: Eur Respir J 2004; 24 : 580-586 Year: 2004 Afterload reduction governs improvement in RV systolic function and ventriculo-arterial adaptation in patients with pulmonary arterial hypertension (PAH) undergoing rapid dose escalation of treprostinil Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases Year: 2016 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005